Wednesday 6 August 2008

How Much Does Atrial Fibrillation Cost The German Health Care System?

� In light of the ageing population, the escalating price impact of diseases common in the elderly on a country's health upkeep budget is of increasing importance.




A country-specific rating of the costs associated with this condition is important for both clinicians and wellness care planners.




A recent study, "The costs of care in atrial fibrillation and the effect of treatment modalities in Germany," published in Value in Health, estimated a disease-related cost of over �660 million to the German healthcare system, with 44% of the costs attributed to hospital in-patient care and 56% for outpatient care. Substantially higher costs were incurred by patients requiring handling to govern their heart rhythm in comparison to those world Health Organization required treatment to decrease their eye rate or other therapies. The study was co-authored by Doreen McBride, Anna Mattenklotz, Stefan Willich and Bernd Br�ggenj�rgen of the Institute for Social Medicine, Epidemiology and Health Economics at the Charit� University Medical Center.




Atrial fibrillation is ane of the most common heart arrhythmias, affecting 6% of the great unwashed over 65 years of age. Because of the associated increased risk of stroke, the treatment of atrial fibrillation includes controlling the increased heart rate and temporary rhythm, as well as preventing virgule through the use of blood thinners.




Says Dr. McBride, "The real-life cost evaluation of this sketch demonstrates pronounced economic burden due to atrial fibrillation. Efforts to reduce the high cost of atrial fibrillation should focus on optimization of current treatment modalities in stroke bar and spunk rhythm ascendency, thereby reducing the need for infirmary admissions."



Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research and help health guardianship leaders to make decisions that are solidly evidence-based. The journal is promulgated bi-monthly and has a regular readership of o'er 3,000 clinicians, decision-makers, and researchers worldwide.




ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care resources wisely, fair, and efficiently.



Value in Health Volume 12 Issue 2 -March/April 2009


ABSTRACT




http://www.ispor.org



More info